Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial

M Provenzano, MJ Puchades, C Garofalo… - Journal of the …, 2022 - journals.lww.com
Background Sodium glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid
receptor antagonists (MRAs) reduce the urinary albumin-to-creatinine ratio (UACR) and …
被引用次数：82 相关文章

Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and their Combination in Patients with Chronic Kidney Disease: A Randomized Cross-Over Clinical Trial

M Provenzano, MJ Puchades, C Garofalo… - Journal of the …, 2022 - research.rug.nl
BACKGROUND: SGLT2 inhibitors and MRAs reduce the urinary albumin-to-creatinine ratio
(UACR) and confer kidney and cardiovascular protection in patients with chronic kidney …

Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and their Combination in Patients with Chronic Kidney Disease: A Randomized Cross-over Clinical Trial

M Provenzano, MJ Puchades, C Garofalo… - JOURNAL OF THE …, 2022 - iris.unicampania.it
Background: SGLT2 inhibitors and MRAs reduce the urinary albumin-to-creatinine ratio
(UACR) and confer kidney and cardiovascular protection in patients with chronic kidney …

Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial

M Provenzano, MJ Puchades, C Garofalo… - Journal of the American …, 2022 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Significance Statement</jats: title>< jats: p> In this randomized
crossover clinical trial in patients with CKD with and without type 2 diabetes, we assessed …

Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.

M Provenzano, MJ Puchades, C Garofalo… - Journal of the …, 2022 - europepmc.org
Background Sodium glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid
receptor antagonists (MRAs) reduce the urinary albumin-to-creatinine ratio (UACR) and …
[HTML] nih.gov

[HTML][HTML] Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical …

M Provenzano, MJ Puchades, C Garofalo… - Journal of the …, 2022 - ncbi.nlm.nih.gov
Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients
with Chronic Kidney Disease: A Randomized Crossover Clinical Trial - PMC Back to Top Skip …
[HTML] inmeli.com

[HTML][HTML] Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and their Combination in Patients with Chronic Kidney Disease: A Randomized Cross-over Clinical …

M Provenzano, M Puchades, C Garofalo… - Journal of the American …, 2022 - inmeli.com
Background: SGLT2 inhibitors and MRAs reduce the urinary albumin-to-creatinine ratio
(UACR) and confer kidney and cardiovascular protection in patients with chronic kidney …

Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial

M Provenzano, MJ Puchades, C Garofalo, N Jongs… - 2022 - pubmed.ncbi.nlm.nih.gov
Background Sodium glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid
receptor antagonists (MRAs) reduce the urinary albumin-to-creatinine ratio (UACR) and …
[HTML] inmeli.com

[HTML][HTML] Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and their Combination in Patients with Chronic Kidney Disease: A Randomized Cross-over Clinical …

M Provenzano, M Puchades, C Garofalo… - Journal of the American …, 2022 - inmeli.com
Background: SGLT2 inhibitors and MRAs reduce the urinary albumin-to-creatinine ratio
(UACR) and confer kidney and cardiovascular protection in patients with chronic kidney …